NASDAQ : BCTX
BriaCell Therapeutics Corp. — Key statistics
Healthcare · Biotechnology · Canada
Last price 3.03 USD (Oct 30, 2026, 2:35 PM EDT) · Market cap 26.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 26.99M |
| Enterprise Value | 5.49M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 8.70M |
| Shares Outstanding | 8.73M |
| Shares Change (YoY) | +1,084.29% |
| Shares Change (QoQ) | +13.30% |
| Owned by Insiders (%) | 2.10% |
| Owned by Institutions (%) | 7.51% |
| Float | 7.86M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.72 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.76 |
| Quick Ratio | 2.76 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -214.79% |
| Return on Assets (ROA) | -99.64% |
| Return on Invested Capital (ROIC) | -137.01% |
| Return on Capital Employed (ROCE) | -231.15% |
| Weighted Average Cost of Capital (WACC) | 12.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.18M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -75.56% |
| 50-Day Moving Average | 3.77 |
| 200-Day Moving Average | 3.81 |
| Relative Strength Index (RSI) | 31.16 |
| Average Volume (20 Days) | 58,214 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 789,493 |
| Short Previous Month | 779,096 |
| Short % of Shares Out | 9.04% |
| Short % of Float | 10.04% |
| Short Ratio (days to cover) | 6.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.05M |
| Pretax Income | -35.33M |
| Net Income | -34.90M |
| EBITDA | -35.93M |
| EBIT | -36.05M |
| Earnings Per Share (EPS) | -$6.99 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 20.54M |
| Total Debt | n/a |
| Net Cash | 20.54M |
| Net Cash Per Share | $2.35 |
| Equity (Book Value) | 15.56M |
| Book Value Per Share | 1.88 |
| Working Capital | 14.06M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -28.65M |
| Capital Expenditures | -127,049 |
| Depreciation & Amortization | 119,335 |
| Net Borrowing | n/a |
| Free Cash Flow | -28.78M |
| FCF Per Share | -$3.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,084.29% |
| Shareholder Yield | -1,084.29% |
| Earnings Yield | -228.35% |
| FCF Yield | -107.34% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 25, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |